GLP-1s Cut Cancer Risk by 50%: The Data Every Man Over 40 Needs to See

Published June 16, 2026: GLP-1 medications were associated with 50%+ reductions in pancreatic, colorectal, and endometrial cancer risk in non-diabetic patients with obesity.

The Data

For men specifically, the colorectal cancer finding is critical — it's the second-leading cause of cancer death in men. Pancreatic cancer, while rarer, is one of the deadliest cancers with a 5-year survival rate under 12%. These findings don't yet justify prescribing GLP-1s for cancer prevention alone.

What This Means for You

But for men already on GLP-1 treatment for weight management, the accumulating evidence of beyond-weight-loss benefits — cardiovascular protection, testosterone restoration, biological aging reversal, and now cancer risk reduction — makes a compelling case for long-term treatment rather than short-term use..

The Practical Application

.

Providers Worth Considering